Literature DB >> 6849757

Optimal sampling times for minimum variance of clearance determination.

M Døssing, A Vølund, H E Poulsen.   

Abstract

1 Clearance of a substance that follows first order kinetics can be determined from multiple plasma concentrations (the standard method) or from only one plasma concentration and an assumed volume of distribution (the simplified method). 2 On the basis of statistical considerations it is shown that the variance of the clearance determined by the standard method has a minimum when the mean sampling time is equal to the reciprocal elimination constant. For the simplified method the variance of the clearance is minimal when the sampling time is equal to the reciprocal elimination constant multiplied by one plus the ratio between the squared coefficients of variation of the concentration and the volume of distribution. 3 The sampling times determined in this way are optimal in the sense that the variance of the clearance estimate will be larger for any alternative choice of the same number of sampling times. In practice, the optimal sampling times can only be determined approximately because the elimination constant is not known exactly. The loss in precision of the clearance estimation arising herefrom will be less if the elimination constant is underestimated than if it is overestimated to the same relative extent. 4 In theory, the simplified method with optimal sampling time will give a more precise clearance determination than the standard method, if the number of optimally spaced sampling times is less than one plus the ratio between the squared coefficients of variation of the concentration and volume of distribution. In studies where each subject serves as his own control and the coefficient of variation of the volume of distribution is relatively small the simplified method will be of higher precision unless the number of samples with the standard method is unusually large.

Mesh:

Year:  1983        PMID: 6849757      PMCID: PMC1427857          DOI: 10.1111/j.1365-2125.1983.tb01491.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.

Authors:  R J Elin; E S Vesell; S M Wolff
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

3.  Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking.

Authors:  R E Vestal; A H Norris; J D Tobin; B H Cohen; N W Shock; R Andres
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

4.  Drug-metabolizing capacity in states of drug dependence and withdrawal.

Authors:  B Ballinger; M Browning; K O'Malley; I H Stevenson
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

5.  Genetic control of drug levels in man: antipyrine.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-07-05       Impact factor: 47.728

6.  Optimum time of blood sampling for determination of glomerular filtration rate by single-injection [51Cr]EDTA plasma clearance.

Authors:  J Bröchner-Mortensen; P Rödbro
Journal:  Scand J Clin Lab Invest       Date:  1976-12       Impact factor: 1.713

7.  Ethanol and antipyrine clearance.

Authors:  M Døssing; P B Andreasen
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

8.  Enhanced antipyrine metabolism in cigarette smokers in Indian population.

Authors:  R Uppal; S K Garg; P R Sharma; C R Nair; R R Chaudhury
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-06

9.  A simple method for determination of antipyrine clearance.

Authors:  M Døssing; H E Poulsen; P B Andreasen; N Tygstrup
Journal:  Clin Pharmacol Ther       Date:  1982-09       Impact factor: 6.875

  9 in total
  9 in total

1.  Comparison of chlorzoxazone one-sample methods to estimate CYP2E1 activity in humans.

Authors:  Iza Kramer; Kim Dalhoff; Jens O Clemmesen; Steffen Loft; Henrik E Poulsen
Journal:  Eur J Clin Pharmacol       Date:  2003-11-11       Impact factor: 2.953

2.  Antipyrine and metronidazole metabolism during occupational exposure to gasoline.

Authors:  M Døssing; S Loft; J Sonne; E Schroeder
Journal:  Int Arch Occup Environ Health       Date:  1988       Impact factor: 3.015

3.  Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

Authors:  H Perrild; L Kayser; H E Poulsen; L Skovsted; B Jørgensen; J M Hansen
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man.

Authors:  J Sonne; J Dragsted; S Loft; M Døssing; F Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Antipyrine clearance in children from single saliva samples.

Authors:  S Loft; O Haxholdt; M Døssing
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

6.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 7.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

8.  Estimating the clearance of amylobarbitone from a single plasma measurement.

Authors:  K Bachmann
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

9.  Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.

Authors:  Devyani Deshpande; Shashikant Srivastava; Jotam G Pasipanodya; Stephen J Bush; Eric Nuermberger; Soumya Swaminathan; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2016-11-01       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.